{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:04:11Z","timestamp":1778043851143,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA214916"],"award-info":[{"award-number":["R01 CA214916"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA168524"],"award-info":[{"award-number":["P30 CA168524"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancers are frequently addicted to oncogenic missense mutant p53 (mutp53). DNAJA1, a member of heat shock protein 40 (HSP40), also known as J-domain proteins (JDPs), plays a crucial role in the stabilization and oncogenic activity of misfolded or conformational mutp53 by binding to and preventing mutp53 from proteasomal degradation. However, strategies to deplete mutp53 are not well-established, and no HSP40\/JDPs inhibitors are clinically available. To identify compounds that bind to DNAJA1 and induce mutp53 degradation, we performed an in silico docking study of ~10 million of compounds from the ZINC database for the J-domain of DNAJA1. A compound 7-3 was identified, and its analogue A11 effectively reduced the levels of DNAJA1 and conformational mutp53 with minimal effects on the levels of wild-type p53 and DNA-contact mutp53. A11 suppressed migration and filopodia formation in a manner dependent on DNAJA1 and conformational mutp53. A mutant DNAJA1 with alanine mutations at predicted amino acids (tyrosine 7, lysine 44, and glutamine 47) failed to bind to A11. Cells expressing the mutant DNAJA1 became insensitive to A11-mediated depletion of DNAJA1 and mutp53 as well as A11-mediated inhibition of cell migration. Thus, A11 is the first HSP40\/JDP inhibitor that has not been previously characterized for depleting DNAJA1 and subsequently conformational mutp53, leading to inhibition of cancer cell migration. A11 can be exploited for a novel treatment against cancers expressing conformational mutp53.<\/jats:p>","DOI":"10.1038\/s41420-022-01229-5","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T16:03:24Z","timestamp":1667232204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen"],"prefix":"10.1038","volume":"8","author":[{"given":"Shigeto","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Parrales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-295X","authenticated-orcid":false,"given":"Mohamed","family":"Alalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.","family":"Schoenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8173","authenticated-orcid":false,"given":"David K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-7958","authenticated-orcid":false,"given":"Tomoo","family":"Iwakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"1229_CR1","first-page":"1113","volume":"76","author":"A-MJCC Tsimberidou","year":"2015","unstructured":"Tsimberidou A-MJCC. Pharmacology. Target Ther Cancer. 2015;76:1113\u201332.","journal-title":"Target Ther Cancer"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333\u20139.","journal-title":"Nature"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1947601911408889","volume":"2","author":"N Rivlin","year":"2011","unstructured":"Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466\u201374.","journal-title":"Genes Cancer"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fonc.2015.00288","volume":"5","author":"A Parrales","year":"2015","unstructured":"Parrales A, Iwakuma T. Targeting oncogenic mutant p53 for cancer therapy. Front Oncol. 2015;5:288.","journal-title":"Front Oncol"},{"key":"1229_CR5","doi-asserted-by":"crossref","unstructured":"Yamamoto S, Iwakuma T. Regulators of oncogenic mutant TP53 gain of function. Cancers. 2019;11:4.","DOI":"10.3390\/cancers11010004"},{"key":"1229_CR6","doi-asserted-by":"crossref","unstructured":"Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008;22:1337\u201344.","DOI":"10.1101\/gad.1662908"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"10360","DOI":"10.1073\/pnas.0805326105","volume":"105","author":"FM Boeckler","year":"2008","unstructured":"Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA. 2008;105:10360\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","volume":"429","author":"X Yue","year":"2017","unstructured":"Yue X, Zhao Y, Xu Y, Zheng M, Feng Z, Hu W. Mutant p53 in cancer: accumulation, gain-of-function, and therapy. J Mol Biol. 2017;429:1595\u2013606.","journal-title":"J Mol Biol"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ccell.2018.07.004","volume":"34","author":"R Schulz-Heddergott","year":"2018","unstructured":"Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi L-C, Bohnenberger H, et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell. 2018;34:298\u2013314.","journal-title":"Cancer Cell"},{"key":"1229_CR10","doi-asserted-by":"crossref","unstructured":"Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552\u201361.","DOI":"10.1056\/NEJMoa073770"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/jcb.25592","volume":"117","author":"G Zhou","year":"2016","unstructured":"Zhou G, Liu Z, Myers JN. TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem. 2016;117:2682\u201392.","journal-title":"J Cell Biochem"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jor.24227","volume":"37","author":"F Tang","year":"2019","unstructured":"Tang F, Min L, Seebacher NA, Li X, Zhou Y, Hornicek FJ, et al. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. J Orthop Res. 2019;37:789\u201398.","journal-title":"J Orthop Res"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/j.ejca.2012.03.001","volume":"48","author":"J Liu","year":"2012","unstructured":"Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, et al. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48:2328\u201338.","journal-title":"Eur J Cancer"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nature14430","volume":"523","author":"EM Alexandrova","year":"2015","unstructured":"Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015;523:352\u20136.","journal-title":"Nature"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.18632\/oncotarget.6634","volume":"7","author":"SV Iyer","year":"2016","unstructured":"Iyer SV, Parrales A, Begani P, Narkar A, Adhikari AS, Martinez LA, et al. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities. Oncotarget. 2016;7:5401\u201315.","journal-title":"Oncotarget"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2015.00249","volume":"5","author":"MP Kim","year":"2015","unstructured":"Kim MP, Zhang Y, Lozano G. Mutant p53: multiple mechanisms define biologic activity in cancer. Front Oncol. 2015;5:249.","journal-title":"Front Oncol"},{"key":"1229_CR17","doi-asserted-by":"crossref","unstructured":"Parrales A, Ranjan A, Iyer SV, Padhye S, Weir SJ, Roy A. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat Cell Biol. 2016;18:1233\u201343.","DOI":"10.1038\/ncb3427"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1038\/s41388-021-01921-3","volume":"40","author":"A Kaida","year":"2021","unstructured":"Kaida A, Yamamoto S, Parrales A, Young ED, Ranjan A, Alalem MA, et al. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Oncogene. 2021;40:5013\u201325.","journal-title":"Oncogene"},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-319-11731-7_4","volume":"78","author":"DM Cyr","year":"2015","unstructured":"Cyr DM, Ramos CH. Specification of Hsp70 function by type I and type II Hsp40. Subcell Biochem. 2015;78:91\u2013102.","journal-title":"Subcell Biochem"},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1007\/s00018-006-6192-6","volume":"63","author":"XB Qiu","year":"2006","unstructured":"Qiu XB, Shao YM, Miao S, Wang L. The diversity of the DnaJ\/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci. 2006;63:2560\u201370.","journal-title":"Cell Mol Life Sci"},{"key":"1229_CR21","doi-asserted-by":"crossref","unstructured":"Zarouchlioti C, Parfitt DA, Li W, Gittings LM, Cheetham ME. DNAJ Proteins in neurodegeneration: essential and protective factors. Philos Trans R Soc Lond B Biol Sci. 2018;373:20160534.","DOI":"10.1098\/rstb.2016.0534"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.2174\/092986609788490159","volume":"16","author":"J Li","year":"2009","unstructured":"Li J, Qian X, Sha B. Heat shock protein 40: structural studies and their functional implications. Protein Pept Lett. 2009;16:606\u201312.","journal-title":"Protein Pept Lett"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1074\/jbc.RA120.014749","volume":"296","author":"X Tong","year":"2020","unstructured":"Tong X, Xu D, Mishra RK, Jones RD, Sun L, Schiltz GE, et al. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. J Biol Chem. 2020;296:100098.","journal-title":"J Biol Chem"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/ncb3427","volume":"18","author":"A Parrales","year":"2016","unstructured":"Parrales A, Ranjan A, Iyer SV, Padhye S, Weir SJ, Roy A, et al. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nat Cell Biol. 2016;18:1233\u201343.","journal-title":"Nat Cell Biol"},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/mc.23097","volume":"58","author":"D Xu","year":"2019","unstructured":"Xu D, Tong X, Sun L, Li H, Jones RD, Liao J, et al. Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53. Mol Carcinog. 2019;58:2052\u201364.","journal-title":"Mol Carcinog"},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84\u201387.","journal-title":"Science"},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9:2100\u201322.","journal-title":"Nat Protoc"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/2472555218813332","volume":"24","author":"J Shaw","year":"2019","unstructured":"Shaw J, Dale I, Hemsley P, Leach L, Dekki N, Orme JP, et al. Positioning high-throughput CETSA in early drug discovery through screening against B-Raf and PARP1. SLAS Discov. 2019;24:121\u201332.","journal-title":"SLAS Discov"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2472555217732014","volume":"23","author":"DE McNulty","year":"2018","unstructured":"McNulty DE, Bonnette WG, Qi H, Wang L, Ho TF, Waszkiewicz A, et al. A high-throughput dose-response cellular thermal shift assay for rapid screening of drug target engagement in living cells, exemplified using SMYD3 and IDO1. SLAS Discov. 2018;23:34\u201346.","journal-title":"SLAS Discov"},{"key":"1229_CR30","doi-asserted-by":"publisher","first-page":"e1004081","DOI":"10.1371\/journal.pcbi.1004081","volume":"11","author":"DK Johnson","year":"2015","unstructured":"Johnson DK, Karanicolas J. Selectivity by small-molecule inhibitors of protein interactions can be driven by protein surface fluctuations. PLoS Comput Biol. 2015;11:e1004081.","journal-title":"PLoS Comput Biol"},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1021\/acs.jcim.5b00572","volume":"56","author":"DK Johnson","year":"2016","unstructured":"Johnson DK, Karanicolas J. Ultra-high-throughput structure-based virtual screening for small-molecule inhibitors of protein-protein interactions. J Chem Inf Model. 2016;56:399\u2013411.","journal-title":"J Chem Inf Model"},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1158\/0008-5472.CAN-17-3728","volume":"78","author":"MA Moses","year":"2018","unstructured":"Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, et al. Targeting the Hsp40\/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer. Cancer Res. 2018;78:4022\u201335.","journal-title":"Cancer Res"},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1074\/jbc.RA120.014749","volume":"296","author":"X Tong","year":"2021","unstructured":"Tong X, Xu D, Mishra RK, Jones RD, Sun L, Schiltz GE, et al. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. J Biol Chem. 2021;296:100098.","journal-title":"J Biol Chem"},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1073\/pnas.97.6.2898","volume":"97","author":"A Wyttenbach","year":"2000","unstructured":"Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, et al. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington\u2019s disease. Proc Natl Acad Sci USA. 2000;97:2898\u2013903.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1229_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65046-5","volume":"10","author":"C Rodr\u00edguez-Gonz\u00e1lez","year":"2020","unstructured":"Rodr\u00edguez-Gonz\u00e1lez C, Lin S, Arkan S, Hansen C. Co-chaperones DNAJA1 and DNAJB6 are critical for regulation of polyglutamine aggregation. Sci Rep. 2020;10:8130.","journal-title":"Sci Rep"},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmb.2012.02.003","volume":"421","author":"JF Abisambra","year":"2012","unstructured":"Abisambra JF, Jinwal UK, Suntharalingam A, Arulselvam K, Brady S, Cockman M, et al. DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau. J Mol Biol. 2012;421:653\u201361.","journal-title":"J Mol Biol"},{"key":"1229_CR37","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/emboj\/18.6.1492","volume":"18","author":"GC Meacham","year":"1999","unstructured":"Meacham GC, Lu Z, King S, Sorscher E, Tousson A, Cyr DM. The Hdj-2\/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J. 1999;18:1492\u2013505.","journal-title":"EMBO J"},{"key":"1229_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61107-x","volume":"10","author":"I Baaklini","year":"2020","unstructured":"Baaklini I, Gon\u00e7alves CC, Lukacs GL, Young JC. Selective Binding of HSC70 and its co-chaperones to structural hotspots on CFTR. Sci Rep. 2020;10:4176.","journal-title":"Sci Rep"},{"key":"1229_CR39","doi-asserted-by":"publisher","first-page":"e0220984","DOI":"10.1371\/journal.pone.0220984","volume":"14","author":"P Kim Chiaw","year":"2019","unstructured":"Kim Chiaw P, Hantouche C, Wong MJH, Matthes E, Robert R, Hanrahan JW, et al. Hsp70 and DNAJA2 limit CFTR levels through degradation. PLoS ONE. 2019;14:e0220984.","journal-title":"PLoS ONE"},{"key":"1229_CR40","doi-asserted-by":"crossref","unstructured":"Yang S, Ren X, Liang Y, Yan Y, Zhou Y, Hu J. KNK437 restricts the growth and metastasis of colorectal cancer via targeting DNAJA1\/CDC45 axis. Oncogene. 2020;39:249\u201361.","DOI":"10.1038\/s41388-019-0978-0"},{"key":"1229_CR41","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1042\/BCJ20160440","volume":"473","author":"E Ergulen","year":"2016","unstructured":"Ergulen E, Becsi B, Csomos I, Fesus L, Kanchan K. Identification of DNAJA1 as a novel interacting partner and a substrate of human transglutaminase 2. Biochem J. 2016;473:3889\u2013901.","journal-title":"Biochem J"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01229-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T16:03:53Z","timestamp":1667232233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01229-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1038\/s41420-022-01229-5","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"437"}}